Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $15.48 up 1.71% from the previous closing price of $15.22. In other words, the price has increased by $1.71 from its previous closing price. On the day, 0.94 million shares were traded. MLYS stock price reached its highest trading level at $15.55 during the session, while it also had its lowest trading level at $14.94.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30. On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Rodman David Malcom sold 11,365 shares for $12.93 per share. The transaction valued at 146,987 led to the insider holds 92,891 shares of the business.
Rodman David Malcom bought 11,365 shares of MLYS for $146,987 on Aug 13 ’25. On Jul 30 ’25, another insider, Levy Adam Scott, who serves as the CFO and Secretary of the company, sold 59,925 shares for $14.76 each. As a result, the insider received 884,372 and left with 132,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 1026249664 and an Enterprise Value of 701333440.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.29, which has changed by 0.29539752 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 9.51%, while the 200-Day Moving Average is calculated to be 17.33%.
Shares Statistics:
Over the past 3-months, MLYS traded about 815.15K shares per day on average, while over the past 10 days, MLYS traded about 1001010 shares per day. A total of 65.73M shares are outstanding, with a floating share count of 42.81M. Insiders hold about 35.42% of the company’s shares, while institutions hold 73.86% stake in the company. Shares short for MLYS as of 1755216000 were 7408973 with a Short Ratio of 9.09, compared to 1752537600 on 7867965. Therefore, it implies a Short% of Shares Outstanding of 7408973 and a Short% of Float of 14.69.
Earnings Estimates
Mineralys Therapeutics Inc (MLYS) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.41 and -$3.8 for the fiscal current year, implying an average EPS of -$2.81. EPS for the following year is -$2.95, with 7.0 analysts recommending between -$2.11 and -$4.01.
